BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 34831031)

  • 21. Bile acids and sphingolipids in non-alcoholic fatty liver disease.
    Jackson KG; Way GW; Zhou H
    Chin Med J (Engl); 2022 May; 135(10):1163-1171. PubMed ID: 35788089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver Steatosis and Steatohepatitis Alter Bile Acid Receptors in Brain and Induce Neuroinflammation: A Contribution of Circulating Bile Acids and Blood-Brain Barrier.
    Fiaschini N; Mancuso M; Tanori M; Colantoni E; Vitali R; Diretto G; Lorenzo Rebenaque L; Stronati L; Negroni A
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.
    Takahashi S; Luo Y; Ranjit S; Xie C; Libby AE; Orlicky DJ; Dvornikov A; Wang XX; Myakala K; Jones BA; Bhasin K; Wang D; McManaman JL; Krausz KW; Gratton E; Ir D; Robertson CE; Frank DN; Gonzalez FJ; Levi M
    J Biol Chem; 2020 Apr; 295(14):4733-4747. PubMed ID: 32075905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bile acid receptors and nonalcoholic fatty liver disease.
    Yuan L; Bambha K
    World J Hepatol; 2015 Dec; 7(28):2811-8. PubMed ID: 26668692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Puri P; Daita K; Joyce A; Mirshahi F; Santhekadur PK; Cazanave S; Luketic VA; Siddiqui MS; Boyett S; Min HK; Kumar DP; Kohli R; Zhou H; Hylemon PB; Contos MJ; Idowu M; Sanyal AJ
    Hepatology; 2018 Feb; 67(2):534-548. PubMed ID: 28696585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Environmental Chemical Contribution to the Modulation of Bile Acid Homeostasis and Farnesoid X Receptor Signaling.
    Taylor RE; Bhattacharya A; Guo GL
    Drug Metab Dispos; 2022 Apr; 50(4):456-467. PubMed ID: 34759011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
    Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
    Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Potential of Bile Acids as Biomarkers for Metabolic Disorders.
    Yin C; Zhong R; Zhang W; Liu L; Chen L; Zhang H
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
    Arab JP; Karpen SJ; Dawson PA; Arrese M; Trauner M
    Hepatology; 2017 Jan; 65(1):350-362. PubMed ID: 27358174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
    Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
    J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The chronic consumption of dietary fructose promotes the gut Clostridium species imbalance and bile acid alterations in developing nonalcoholic fatty liver disease.
    Zhang D; Wang H; Liu A; Wang S; Xu C; Lan K; Xiang W; Zhu K; Xiao Y; Fu J; Jiang R; Chen W; Ni Y
    J Nutr Biochem; 2023 Nov; 121():109434. PubMed ID: 37661068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions.
    Wei M; Tu W; Huang G
    Front Microbiol; 2024; 15():1341938. PubMed ID: 38887706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
    Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
    J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in Bile Acid Metabolism, Transport, and Signaling as Central Drivers for Metabolic Improvements After Bariatric Surgery.
    Browning MG; Pessoa BM; Khoraki J; Campos GM
    Curr Obes Rep; 2019 Jun; 8(2):175-184. PubMed ID: 30847736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice.
    Chevre R; Trigueros-Motos L; Castaño D; Chua T; Corlianò M; Patankar JV; Sng L; Sim L; Juin TL; Carissimo G; Ng LFP; Yi CNJ; Eliathamby CC; Groen AK; Hayden MR; Singaraja RR
    FASEB J; 2018 Jul; 32(7):3792-3802. PubMed ID: 29481310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways.
    Wang Y; Tai YL; Zhao D; Zhang Y; Yan J; Kakiyama G; Wang X; Gurley EC; Liu J; Liu J; Liu J; Lai G; Hylemon PB; Pandak WM; Chen W; Zhou H
    Cells; 2021 Jan; 10(2):. PubMed ID: 33494295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
    Tan X; Liu Y; Long J; Chen S; Liao G; Wu S; Li C; Wang L; Ling W; Zhu H
    Mol Nutr Food Res; 2019 Sep; 63(17):e1900257. PubMed ID: 31095863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease.
    Lake AD; Novak P; Shipkova P; Aranibar N; Robertson D; Reily MD; Lu Z; Lehman-McKeeman LD; Cherrington NJ
    Toxicol Appl Pharmacol; 2013 Apr; 268(2):132-40. PubMed ID: 23391614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.